Predict MEDiX AI Inc (PMEDF)

[JohnCM]

Cultivar Holdings Inc. Announces Its Name Change to Predictmedix Inc.

INVESTORINTEL
April 9, 2020

Predictmedix Inc. (CSE:PMED) (CNSX:PMED.CN) (OTC:PMEDF) (formerly Cultivar Holdings Inc.) (the “Company”) is pleased to announce that it has completed its name change from “Cultivar Holdings Inc.” to “Predictmedix Inc.” (the “Name Change”). The articles of the Company provide the directors with the authority to change the name of the Company by way of directors resolution without consent of the shareholders.

Common shares owned by shareholders of the Company will automatically be adjusted as a result of the Name Change and no further action is required to be taken by shareholders. The CUSIP number assigned to the Company’s common shares following the name change is: CUSIP 74040L100 (ISIN CA74040L1004).In connection with the Name Change, the Company’s trading symbol, as listed on the CSE and the OTCQB have also been changed from “CULT” to “PMED”, and from “CVRHF” to “PMEDF”, respectively.The Company has also retained the services of the well-respected British Columbia corporate communications company, MarketSmart Communications Inc.

(“MarketSmart”). MarketSmart will help the Company develop and implement a strategic corporate communications program to increase its visibility and exposure among industry stakeholders and investors across Canada and U.S. In connection with the engagement, the Company has agreed to pay MarketSmart a monthly fee of $6,000 (plus GST) for six (6) months, and has granted options to purchase up to 200,000 Company common shares at $0.15 per share for a period of twelve (12) months from the issue date. The options will immediately vest upon issuance.

About Predictmedix Inc. Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive and cutting-edge tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points.

Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice. The Company has partnered with Tech Mahindra and Hindalco to help expedite the launch of its impairment technology, as well as the prestigious Indian Institute of Technology.The Company is also developing cutting edge screening for the healthcare industry.

The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19).

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.